Sign inJoin waitlistJoin the waitlist

DE

David Eichenbaum

Director of Research · University of Miami/Jackson Health System

Credentials: · · · ·

History

Research · University of Miami/Jackson Health System
Present
University of Miami/Jackson Health System
Present

University of South Florida
2002–2005
Preliminary or Transitional Year
2001–2002
University of South Florida College of Medicine
1997–2001

Research

Efficacy, durability, and safety of intravitreal faricimab with extended dosing up to every 16 weeks in patients with diabetic macular oedema (YOSEMITE and RHINE): two randomised,…
The Lancet · 2022 · 396 citations
Efficacy and safety of avacincaptad pegol in patients with geographic atrophy (GATHER2): 12-month results from a randomised, double-masked, phase 3 trial
The Lancet · 2023 · 299 citations
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial
The Lancet · 2024 · 228 citations

CW
Charles Wykoff
15 papers
AK
Arshad Khanani
12 papers
VS
Veeral Sheth
9 papers
NH
Nancy Holekamp
6 papers
Carl Regillo
5 papers
CB
Caroline Baumal
5 papers
DK
Daniel Kiernan
5 papers
DL
David Lally
5 papers
JH
Jeffrey Heier
5 papers
Rishi Singh
5 papers
CD
Carl Danzig
4 papers
LC
Lloyd Clark
4 papers

Clinical trials

Effect on Pain and Inflammation With DEXTENZA Treatment in Patients Undergoing Intravitreal Anti-VEGF Injections
Principal investigator · Terminated · Phase 4
Retina Vitreous Associates of Florida
2020–2023
Dosing Study of Ranibizumab for Diabetic Retinal and Macular Edema
Principal investigator · Completed · Phase 2
Retina Vitreous Associates of Florida
2011–2016
A Study to Investigate Efficacy and Safety of FWY003 Compared With Placebo in Participants With Geographic Atrophy Secondary to Age-related Macular Degeneration
Site PI · Recruiting · Phase 2
Novartis Pharmaceuticals
2026–2029
Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
Site PI · Recruiting · Phase 3
4D Molecular Therapeutics
2025–2029